Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 51Oligometastatic Prostate Cancer 2Neoplasm Metastasis 2Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 2Metastatic Castration-resistant Prostate Cancer 2Triple Negative Breast Neoplasms 1Stage IV Prostate Adenocarcinoma AJCC v7 1Prostate CA 1Prostate Adenocarcinoma 1PSA Level Greater Than 0.03 1Non-metastatic, Hormone naïve Prostate Cancer 1Lymphatic Metastasis 1Hormone Sensitive Prostate Cancer 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

enzalutamide 3testosterone 17 beta-cypionate 2darolutamide 2abiraterone 2Docetaxel 2Androgen Antagonists 2sipuleucel-T 1pamiparib 1olaparib 1lactitol 1fluciclovine F-18 1enfortumab vedotin 1cabazitaxel 1avelumab 1Standard of Care 1Selegiline 1Prednisolone 1Pluvicto 1PSMA-617 1Gonadotropin-Releasing Hormone 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Metastatic Castration-resistant Prostate Cancer × Androgen Antagonists × Clear all
NCT07476001 2026-05-15

Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting
12 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT07553988 2026-04-28

A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer

R-Pharm

Phase 2 Active not recruiting
120 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡